Get startedLog in
    Picture of Genmab A/S logo

    GMAB — Genmab A/S News Story

    0.000.00%
    dk flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapHigh Flyer
    All News

    Brief: Genmab Says Phase 3 EPCORE FL-1 Clinical Trial Met Dual Primary Endpoints In Patients With R/R FL

    Picture of Genmab A/S logoGenmab A/S
    07/08/2025 16:34
    Aug 7 (Reuters) - Genmab A/S GMAB.CO:

GENMAB ANNOUNCES PHASE 3 EPCORE® FL-1 CLINICAL TRIAL MET DUAL PRIMARY ENDPOINTS IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

GENMAB - FDA HAS ACCEPTED FOR PRIORITY REVIEW NEW SBLA FOR EPCORITAMAB PLUS R(2), WITH ACTION DATE OF NOVEMBER 30

Source text: ID:nGNX2rWWnk

Further company coverage: GMAB.CO

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Genmab A/S

    See all news